Adial Pharmaceuticals, Inc (ADIL)

Etorro trading 970x250
Adial Pharmaceuticals, Inc (ADIL) Logo

About Adial Pharmaceuticals, Inc

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 for the treatment of alcohol use disorder. The company was founded in 2010 and is based in Charlottesville, Virginia. Address: 1180 Seminole Trail, Charlottesville, VA, United States, 22901

Adial Pharmaceuticals, Inc News and around…

Latest news about Adial Pharmaceuticals, Inc (ADIL) common stock and company :

Is Adial Pharmaceuticals, Inc. (ADIL) Outperforming Other Medical Stocks This Year?
12 Jan, 2022 Yahoo! Finance

Here is how Adial Pharmaceuticals, Inc. (ADIL) and Albireo Pharma (ALBO) have performed compared to their sector so far this year.

Adial Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2022 Conference
10 Jan, 2022 Yahoo! Finance

CHARLOTTESVILLE, Va., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer of Adial, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022. Adial’s presentation will be available

Year End Update for this Up and Coming NASDAQ at the forefront of innovations in healthcare Featuring AI and Immunotherapies. Avalon GloboCare Corp. (NASDAQ:AVCO); Is AVCO the Next BFRI?
10 Jan, 2022 FinancialContent
Monday 1/3 Insider Buying Report: ADIL, IDN
03 Jan, 2022 FinancialContent

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.

Adial Pharmaceuticals Completes Private Placement of Common Stock at $4.00 Per Share
22 Dec, 2021 Yahoo! Finance

CHARLOTTESVILLE, Va., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has received the balance of $720,000 due from the $800,000 private placement previously disclosed by the Company on November 10, 2021 (the “Offering”). The shares of common stock sold in the Offerin

NASDAQ at the forefront of innovations in healthcare. Avalon GloboCare Corp. (NASDAQ:AVCO): AVCO's Filtration Tech Could Help Stop Life-Threatening Cytokine Storm in COVID-19 Patients
22 Dec, 2021 FinancialContent
NASDAQ Companies Including: Biofrontera (NASDAQ:BFRI), Avalon GloboCare Corp. (NASDAQ:AVCO), Palantir Technologies (NYSE: PLTR) and Nvidia (NVDA) lead the Charge and Artificial Intelligence (AI) is at
16 Dec, 2021 FinancialContent
NASDAQ Company Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development: Avalon Globocare, Inc. (NASDAQ: AVCO)
09 Dec, 2021 FinancialContent
Adial Announces Cary J. Claiborne, a Renowned Pharmaceutical Executive and Current Board Member, has Joined the Company as Chief Operating Officer
08 Dec, 2021 Yahoo! Finance

CHARLOTTESVILLE, Va., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Cary J. Claiborne as Chief Operating Officer. Mr. Claiborne will continue to serve on the Board of Directors. In his new role, Mr. Claiborne will be responsible for overseeing the Company’s strategic growth initiat

Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Cancer
29 Nov, 2021 Yahoo! Finance

PNV2 demonstrates reduction of metastases in animal modelCHARLOTTESVILLE, Va., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced positive pre-clinical data for PNV2 in an animal model of triple negative breast cancer (TNBC). Based on the strength of this data, Purnovate, Inc.,

REMINDER: Adial Pharmaceuticals to Host Conference Call Thursday, November 18, 2021 at 11:00AM Eastern to Provide Clinical Update and Discuss Latest Developments
17 Nov, 2021 Yahoo! Finance

CHARLOTTESVILLE, Va., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, reminds investors that it will host a conference call at 11:00 A.M. Eastern Time on Thursday, November 18, 2021 to provide a clinical update and discuss the latest business developments. The conference call will be availab

Adial Pharmaceuticals Announces Private Placement of Common Stock at $4.00 Per Share and Cash Exercise of Stock Options
10 Nov, 2021 Yahoo! Finance

Financing to support clinical trial pathway for non-opioid drug candidate for treatment of painCHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has received funds and capital commitments totaling $1,255,000; $800,000 from the sale of shares of com

Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments
09 Nov, 2021 Yahoo! Finance

CHARLOTTESVILLE, Va., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it will host a conference call at 11:00 A.M. Eastern Time on Thursday, November 18, 2021 to provide a clinical update and discuss the latest business developments. The conference call may be accessed using

Adial Appoints Renowned Pharmaceutical Executive Cary J. Claiborne to Board of Directors
03 Nov, 2021 Yahoo! Finance

CHARLOTTESVILLE, Va., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Cary J. Claiborne to the Board of Directors, increasing the number of board members to seven. Mr. Claiborne previously served as CFO and board member of Indivior PLC, a publicly traded specialty pharmaceutical comp

Adial Pharma-Backed Purnovate Selects PNV-5030 As Pain Management Candidate
21 Oct, 2021 FinancialContent

Adial Pharmaceuticals Inc(NASDAQ: ADIL) hasannounced data in a preclinical modelof pain reduction. Based on the ...

12 Health Care Stocks Moving In Thursday's Intraday Session
21 Oct, 2021 FinancialContent

Gainers Sio Gene Therapies (NASDAQ:SIOX) stock moved upwards by 22.79% to $2.64 during Thursday's regular session. ...

Adial Announces Positive Pre-Clinical Data for Purnovate’s PNV-5030 as a Drug Candidate for the Treatment of Pain
21 Oct, 2021 Yahoo! Finance

Results suggest potential of PNV-5030 as both a standalone and combination therapy to reduce or eliminate opioid use and achieve meaningful pain reduction Clinical trial expected to commence in 2022 CHARLOTTESVILLE, Va., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced positive data in a pre-clinical mo

Adial Pharmaceuticals to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021
18 Oct, 2021 Yahoo! Finance

CHARLOTTESVILLE, Va., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer and President of Adial Pharmaceuticals, will present at the Dawson James Securities Small Cap Growth Conference being held on October 21, 2021 at the Wyndham Gr

This NASDAQ has Life Saving Advances in Today's Most Critical Bio-Science Fields of Cancer and Immune Related Disease, Including COVID-19: Avalon GloboCare Corp. (NASDAQ: AVCO)
13 Oct, 2021 FinancialContent
Avalon GloboCare's Advanced Filtration Tech Could Help Stop Life-Threatening Cytokine Storm in COVID-19 Patients
07 Oct, 2021 FinancialContent

Image Provided by Pixabay Cytokine storm has made frequent appearances in the news lately as a life-threatening complication in ...

Adial Pharmaceuticals to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Tuesday, October 5, 2021
05 Oct, 2021 FinancialContent
36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021
04 Oct, 2021 Yahoo! Finance

RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th \- 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The Fall Harvest - Best Ideas from the Buy Side: VIRTUAL begins on Tuesday, October 5th, 2021, with company presentations beginning at 8:30 am Eastern Time.

Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Peri
30 Sep, 2021 FinancialContent
Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period – Trial Completion Anticipated Q1 2022
30 Sep, 2021 Yahoo! Finance

CHARLOTTESVILLE, Va., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces that greater than 50% of patients expected to complete the ONWARD™ Phase 3 trial evaluating AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes re

Adial Pharmaceuticals Announces Research Collaboration Agreement with the University of Virginia to Advance Next Generation Adenosine Compounds for Wound Healing
28 Sep, 2021 FinancialContent

Collaboration targeting development of new adenosine formulations that can be absorbed transdermally

12 Health Care Stocks Moving In Monday's Pre-Market Session
27 Sep, 2021 FinancialContent

Gainers Syndax Pharmaceuticals (NASDAQ:SNDX) shares moved upwards by 8.94% to $20.48 during Monday's pre-market ...

Adial CEO William Stilley Invited to Participate in Maxim Group’s Virtual Panel Series Conference: “Disruptors in the Mental Health Space”
15 Sep, 2021 FinancialContent
Sysorex Elects Nasdaq-Listed Company CEO William Stilley to Board of Directors
13 Sep, 2021 FinancialContent
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
08 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07 Sep, 2021 FinancialContent

Adial Pharmaceuticals, Inc (ADIL) is a NASDAQ Common Stock listed in , ,

970x250